DE69937057D1 - Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen - Google Patents

Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen

Info

Publication number
DE69937057D1
DE69937057D1 DE69937057T DE69937057T DE69937057D1 DE 69937057 D1 DE69937057 D1 DE 69937057D1 DE 69937057 T DE69937057 T DE 69937057T DE 69937057 T DE69937057 T DE 69937057T DE 69937057 D1 DE69937057 D1 DE 69937057D1
Authority
DE
Germany
Prior art keywords
tyr
treatment
rheumatoid arthritis
skin diseases
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69937057T
Other languages
English (en)
Other versions
DE69937057T2 (de
Inventor
Peter Lloyd Amlot
Max H Schreier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9816281.1A external-priority patent/GB9816281D0/en
Priority claimed from GBGB9912460.4A external-priority patent/GB9912460D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE69937057D1 publication Critical patent/DE69937057D1/de
Application granted granted Critical
Publication of DE69937057T2 publication Critical patent/DE69937057T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69937057T 1998-07-27 1999-07-26 Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen Expired - Lifetime DE69937057T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9816281 1998-07-27
GBGB9816281.1A GB9816281D0 (en) 1998-07-27 1998-07-27 Organic compounds
GBGB9912460.4A GB9912460D0 (en) 1999-05-27 1999-05-27 Organic compounds
GB9912460 1999-05-27
PCT/EP1999/005316 WO2000006604A2 (en) 1998-07-27 1999-07-26 Use of cd25 binding molecules in the treatment of rheumatoid arthritis or skin diseases

Publications (2)

Publication Number Publication Date
DE69937057D1 true DE69937057D1 (de) 2007-10-18
DE69937057T2 DE69937057T2 (de) 2008-05-29

Family

ID=26314120

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69937057T Expired - Lifetime DE69937057T2 (de) 1998-07-27 1999-07-26 Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen

Country Status (11)

Country Link
US (1) US20020110558A1 (de)
EP (1) EP1100829B1 (de)
JP (1) JP3973360B2 (de)
AT (1) ATE372349T1 (de)
AU (1) AU5728699A (de)
CY (1) CY1107785T1 (de)
DE (1) DE69937057T2 (de)
DK (1) DK1100829T3 (de)
ES (1) ES2291040T3 (de)
PT (1) PT1100829E (de)
WO (1) WO2000006604A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0007911D0 (en) * 2000-03-30 2000-05-17 Novartis Ag Organic compounds
ES2314067T3 (es) * 2001-04-06 2009-03-16 University Of Bristol Uso de moleculas de enlace cd 25 en pacientes resistentes a los esteroides.
AU2004275860A1 (en) * 2003-09-23 2005-04-07 Pdl Biopharma, Inc. Treatment of respiratory diseases with anti-IL-2 receptor antibodies
GB0507696D0 (en) * 2005-04-15 2005-05-25 Novartis Ag Organic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU631545B2 (en) * 1988-04-15 1992-12-03 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
HUT60768A (en) * 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules

Also Published As

Publication number Publication date
EP1100829A2 (de) 2001-05-23
WO2000006604A3 (en) 2000-06-15
ATE372349T1 (de) 2007-09-15
AU5728699A (en) 2000-02-21
EP1100829B1 (de) 2007-09-05
DK1100829T3 (da) 2007-12-27
JP3973360B2 (ja) 2007-09-12
JP2002521491A (ja) 2002-07-16
PT1100829E (pt) 2007-12-06
CY1107785T1 (el) 2013-06-19
DE69937057T2 (de) 2008-05-29
ES2291040T3 (es) 2008-02-16
WO2000006604A2 (en) 2000-02-10
US20020110558A1 (en) 2002-08-15

Similar Documents

Publication Publication Date Title
CY1110033T1 (el) Τεχνητα ανθρωπινα θεραπευτικα αντισωματα εναντια σε ισομορφες cd45
PL359854A1 (en) Antibodies to human mcp-1
GEP20074222B (en) Antibodies to cd40
HUP0401560A2 (hu) Terápiás kötőmolekulák
PE20011219A1 (es) ANTICUERPOS PARA IL-1ß HUMANA
DE60333228D1 (de) Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
WO2003060080A3 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
NZ594275A (en) B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
IL189629A0 (en) Compositions containing human ctla-4 antibodies
DE60135029D1 (de) Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
PL401886A1 (pl) Neutralizujace o wysokim powinowactwie izolowane ludzkie przeciwcialo anty-TNF-alfa, zastosowanie tego przeciwciala, krysztal zawierajacy ludzkie przeciwcialo anty-TNF-alfa i preparat zawierajacy ten krysztal
DE60142590D1 (de) Verwendung von Botulinum Toxin zur Behandlung von post-operative Schmerzen
DE69633717D1 (de) Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis
BRPI0511782A (pt) anticorpos anti-cd3 e métodos de uso dos mesmos
DE60238987D1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
CY1107785T1 (el) Χρηση του βασιλιξιμαμπ στη θεραπεια της ρευματοειδους αρθριτιδας ´η νοσων του δερματος
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
BR0109549A (pt) Utilização de moléculas que se ligam a cd25 no tratamento de doenças inflamatórias do trato gastrointestinal
NO20033718L (no) Syntetiske humane peptider og farmasöytiske sammensetninger omfattende disse for behandling av systemisk lupus erythematosus
TH53886A (th) แอนติบอดี้ต่อ il-1b ในมนุษย์
TH64455A (th) สารภูมิต้านทาน mcp-1 ในมนุษย์
TH53886B (th) แอนติบอดี้ต่อ il-ib ในมนุษย์

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN